The goal of this study was to assess the effects of the Hematopoietic Progenitor Cells (HSCs) on full-thickness cutaneous wounds healing in rabbits. Twenty clinically healthy adult New Zealand White rabbits were used in this study; under aseptic technique and general anesthesia full-thickness excisional cutaneous wound; 20 mm x 20 mm were made on the back. The rabbits were randomly partitioned into two. In first group considered as control group, the wounds were treated with 3 ml of saline solution. In second group (Hematopoietic Progenitor Cells group); wounds were treated with 5x106 hematopoietic progenitor cells. The result of molecular evaluation along the interval of following-up recorded a significant difference of the level Fibroblasts Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) recorded at 7, 14 and 35-day post-surgical operation in hematopoietic progenitor cells group compare than control group. These outcomes were parallel with the finding of the clinical and histopathological assessment showed that hematopoietic progenitor cells group reduces inflammation and promotes epithelialization during 3th weeks with increased vasculature than those in untreated wounds. This study confirms that local implantation of hematopoietic progenitor cells leads to enhance and develop of cutaneous wound healing in rabbit model.

No abstract

No abstract

Colon cancer is the second most popular cause of death. is a important public health issue in developed countries for many years because of its frequency even with the screening and preventative strategies. It stills the second most common cancer in women and third prevalent cancer in men. Like other tumors. The most drug resistance subsets of cancer cells with high proliferation capacity are colon cancer stem cells (CCSCs) with self renewal and multi differentiation capacities. recently indicate that aldehyde dehydrogenase have role in drug resistance ALDH1 and ALDH2 have prognostic and clinicopathological value in colon cancer. The research involved 60 patients (both men and women) ranging in age from 35 to 65 years old. The samples taken from the Ministry of Health and Environment the medical city hospital’s histology laboratory, the Department of Education Laboratories. Colon cancer samples were divided into three groups: group I contained 20 samples from patients recently diagnosed with colon cancer, group II included samples from relapse patients who received chemotherapy but the tumor relapsed, and group III are resistance patient. This study was planned to evaluate the ALDH1 and ALDH2 as a marker for colon cancer stem cell.The percentage of the positivity forALDH1 and ALDH 2 shows in Figs. 3-7. The result are different between groups. Group one (new diagnosis patients) recorded low expression forALDH1 and ALDH2 about 33% forALDH1 and 48% forALDH2 in comparison with group II (relapsed patient) that represented moderate expression to the marker ( 63% and 72% forALDH1 and ALDH2, respectively). While, the higher expression was for group III (resistance patient) with percent of expression 80% and 90%

No abstract